ABBV-9832

N/A

Report date: 2026/05/23 20:00:57

Base Information

Drug NameABBV-9832
Drug Alias NameLutikizumab/RavagalimabABBV-9832
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionInterleukin-1 alpha inhibitorsInterleukin-1 beta inhibitorsTumor necrosis factor receptor superfamily member 5 inhibitors
TargetsInterleukin-1 alphaInterleukin-1 betaTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[12] 
CombinationsYes LutikizumabRavagalimab
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A